Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. The Company is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. Basilea has successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, the Comany has preclinical and clinical anti-infective assets in it's portfolio.